LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of approximately 3% during the forecast period, according to their latest report.
The research study covers the present scenario and growth prospects of the global CNS disorders therapeutics market for 2016-2020. To estimate the market size, the report considers revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.
Request a sample report: http://www.technavio.com/request-a-sample?report=52729
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Technavio healthcare and life sciences analysts highlight the following four factors that are contributing to the growth of the global CNS disorders therapeutics market:
- Special regulatory designations for CNS disorders
- New DMD approvals for AD, PD, and MS
- Development of novel therapeutics using innovative technologies
- High growth potential of mAbs
Special regulatory designations for CNS disorders
Special regulatory designations such as orphan, breakthrough, and fast track, are assigned to the drugs by the US FDA and European Medicines Agency (EMA), which help in the rapid penetration of these drugs in the market. Fast track designations are assigned to drugs used in the treatment of serious conditions with high unmet needs. Orphan drug designations are assigned for the drugs used in the treatment of rare diseases.
In the EU, orphan drugs are offered protocol assistance and 10-year patent exclusivity in the market. In Japan, orphan drug designation and approvals are managed case-by-case with incentives in the form of financial aid covering costs of clinical trials or tax exemptions. “These designations also help in expediting the approval process for the drugs, thus enabling early entry of the new drugs into the market,” says Barath Palada, a lead analyst at Technavio for central nervous system research.
New disease modifying drugs (DMD) approvals for AD, PD, and MS
Currently, the therapies for Alzheimer's disease (AD) and Parkinson’s disease (PD) mainly focus on providing symptomatic relief, failing to treat the underlying cause of the disease. The lack of DMDs unnecessarily prolongs the treatment schedule, thereby increasing healthcare costs. Similarly, the PD drugs market represents a significant unmet medical need due to the lack of DMDs.
However, the launch of safe and efficient DMDs that could modify the progression of the diseases, is expected to change the treatment strategies that are currently followed and will increase the revenue generated by the global CNS disorders market.
Development of novel therapeutics using innovative technologies
The technological advancements in the field of CNS drugs have led to the development of novel molecules for the treatment of CNS diseases. For instance, Aprecia Pharmaceuticals is engaged in the development of Spritam (levetiracetam) using ZipDose technology, which uses a three-dimensional printing (3DP) platform. In this process, a porous, water-soluble matrix is prepared by binding multiple layers of powder using an aqueous fluid. This soluble matrix disintegrates rapidly, which helps in the precise administration and delivery of high doses of drugs. The drug was approved by the US FDA in August 2015.
Similarly, SciFluor is engaged in the development of fluorine-enabled small molecule therapeutics. Using this platform, the company has developed SF0034 that acts as a selective KCNQ2/3 activator. This drug was found to show its activity in epilepsy and tinnitus. “The development of such drugs with novel mechanism of action (MOA), or by using new technologies to provide potential benefits are expected to increase the global CNS disorders therapeutics market growth,” says Barath.
High growth potential of mAbs
The understanding of a disease at the molecular level increases the development and use of biologics in the treatment. Biologics have a high affinity toward specific disease cells. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals. They will continue to out-perform pharmaceuticals in terms of product sales, as there is an increasing need for effective treatment options.
Biologics that treat musculoskeletal disorders are made from proteins. Their MOA is inhibiting the action of the key chemicals or cells involved in the nervous system. Few of the mAbs used to treat CNS disorders are natalizumab, daclizumab, and alemtuzumab. Other than these mAbs, there are many other mAbs for the treatment of CNS disorders, which are in different stages of the development pipeline.
Browse Related Reports:
- Global Generic Drugs Market 2016-2020
- Global Transcriptomics Market 2016-2020
- Global Insomnia Market - Market Research Analysis 2015-2019
Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact enquiry@technavio.com with your requirements and our analysts will be happy to create a customized report just for you.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
